LMN 1001
Alternative Names: LMN-1001Latest Information Update: 12 Sep 2026
At a glance
- Originator Lumen Bioscience
- Class Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Viral infections
Most Recent Events
- 05 Sep 2026 Phase-I clinical trials in Viral infections (In volunteers) (Intranasal) prior to September 2026
- 05 Sep 2026 Phase-I clinical trials in Viral infections (Prevention) (Intranasal) prior to September 2026
- 11 May 2023 Lumen Bioscience has worldwide patent protection for its proprietary drug development technology platform (Lumen Bioscience pipeline, May 2023)